Meta-Analysis of Psychopharmacologic Treatment of Child and Adolescent Depression: Deconstructing Previous Reviews, Moving Forward

John W Maag*1, Mickey Losinski2 and Antonis Katsiyannis3

1University of Nebraska-Lincoln, USA
2Kansas State University, USA
3Clemson University, USA

Abstract

The proliferation of Selective Serotonin Reuptake Inhibitors (SSRIs) in the 1980s led to increased use of antidepressant medications for children and adolescents with Major Depressive Disorder (MDD). Since then, there have been 18 reviews of this literature with nine being meta-analytic. Many of these meta-analyses suffer from several methodological problems: did not statistically compare medication efficacy, included only randomized placebo control trials, calculated response rate rather than risk-difference and odds ratio, were conducted prior to the 2009 publication of the PRISMA meta-analyses standards, rarely addressed publication bias, and failed to conduct meta-regressions to account for moderator variables. The purpose of the present meta-analysis was to address each of these limitations. Results indicated SSRIs were the most effective class of medication with Sertraline having the highest response rate and Citalopram having the lowest response rate. Overall, Nefazodone had the highest response rate of any medication regardless of class, although there was a relatively small sample size (n = 39). When examining publication bias, only SSRIs had statistically significant positive findings. In terms of moderator variables, RCTs and open-label trials predicted response rate, as did age and gender (females).

Keywords: Depression; Psychopharmacologic; Meta-analysis; Children; Adolescents; Treatment; Antidepressant

Introduction

Major depressive disorder (MDD) is a chronic and recurrent condition that effects approximately 2% of children and 6% of adolescents [1,2]. Many children with MDD experience significant psychosocial impairments and require multimodal treatments including pharmacologic agents [3]. The proliferation of selective serotonin reuptake inhibitors (SSRIs) in the 1980s, with a wider margin of safety than tricyclic antidepressants, has led to their increased use among children and adolescents [4]. Nevertheless, SSRIs were included in the 2007 Food and Drug Administration (FDA) updated black box warning label that targeted the risk for suicidal thinking and behavior [5]. However, in a meta-analysis of the literature, Bridge et al. [6] found evidence that the benefits of antidepressants for children and adolescents appear to be much greater than risks of suicidal thoughts or behavior.

There is still a considerable amount of undetermined information and speculation concerning the use of antidepressants with children and adolescents even though there have been approximately 18 previously published reviews and analyses on this subject from 1995 through 2012. Part of the reason is that many of these reviews were purely descriptive and did not statistically synthesize (i.e., meta analyze) findings of the research [1,4,7-10]. They also had different foci including, but not limited to, effects of medications specifically on treatment resistant depression [11], safety of medications [9], and current issues associated with pharmacological treatment of childhood and adolescent depression [12].

There have been several reviews of the literature using meta-analytic techniques, but these too have methodological issues and different foci. First, the majority of the reviews examined only randomized placebo control trials [6,13-19]. Second, most studies used response rate as the primary effect measure, with only one utilizing risk-difference (RD) [6] and two using Odds Ratios (OR) [15,20]. Third, many of these analyses occurred prior to, or did not ascribe to, the Preferred Reporting Items for the Systematic Reviews and Meta-Analyses (PRISMA) [21]. Fourth, because many of the reviews did not follow PRISMA guidelines, only three had replicable descriptions [6,19,20]. Finally, most reviews focused solely on SSRIs [6] and did not include third generation medications (e.g., venlafaxine, reboxetine, nefazodone, mirtazapine). Their analysis also included children with anxiety disorders, and only randomized placebo control trials.

In addition to these different foci, there is an important issue in meta-analyses that none of the previous syntheses addressed: the specific publication bias of the “file drawer” problem [22]. Instead, the importance of addressing this problem when assessing the efficacy and safety of antidepressants. The basic notion of the file drawer problem is that statistically nonsignificant results are less likely to be published [23,24]. Consequently, the effect size obtained from a meta-analysis is likely to be distorted and that the exaggerations are strongest when the true effect size approaches zero [25]. However, if the missing studies are randomly omitted there is no systematic impact on the effect size [23]. Conversely, if there is a systematic omission from a literature synthesis (i.e., consistent lack of publishing nonsignificant results), readers and reviewers of the meta-analysis may draw the wrong conclusion about what that body of research shows [26]. Consequently, there is a continuing and pervasive concern with meta-analytic literature regarding the universality and consequences of the file drawer phenomenon on the synthesis of research [27].
The purpose of the present meta-analysis was to extend the findings and analytic methods of previous reviews by examining all published empirical studies regarding antidepressant medication to treat depression in children and adolescents. Specifically, methodological limitations of previous reviews were addressed by (a) statistically comparing differential efficacy of medication classes and types, (b) including open-ended trials as well as RCTs, (c) calculating odds ratio in addition to traditional response rate, (d) applying the 2009 PRISMA standards, (e) addressing the specific publication bias of the file drawer problem, (f) and conducting meta-regressions to account for the moderator variables of age, gender, treatment length, study design, and medication class.

Method

According to guidelines published in the PRISMA statement, there are 12 items that must be addressed in the methods section of meta-analyses that evaluate health interventions: protocol and registration, eligibility criteria, information sources, search strategy, study selection, data collection process, data items, risk of bias in individual studies, summary measures, synthesis of results, risk of bias across studies, and any additional analyses [21]. Each item must be addressed to ensure clarity and transparency of conducting systematic reviews, although, they do not have to appear as 12 separate sections.

Information sources for the present meta-analysis included searching the following online databases: Medline, Psych INFO, and ERIC. The following Boolean phrase was used for each source: ("Depression") AND ("medication" OR "Anti-depressant") AND ("Child" OR "youth" OR "student" OR "adolescent") with the last search completed on September 3, 2013. The study criteria were limited to reports of empirical studies, quantitative studies, literature reviews, clinical trials, systematic reviews, and meta-analyses.

Eligibility criteria

There were four eligibility criteria to be included in the current review and analysis: (a) type of study, (b) type of participants, (c) type of intervention, and (d) type of outcome measures. First, articles were published in English, reported results of empirical data, and were quantitative in design. Second, participants were children or adolescents between the ages of 0 to 18 years with Major Depressive Disorder (MDD) as the primary diagnosis. Depressive disorders as a secondary comorbid condition to another psychiatric condition or individuals with bipolar disorder were not considered. Third, studies were considered that examined the efficacy of a physician-prescribed medication and oversight intended to reduce depressive symptoms. In order to be included, the medication must have been one condition in isolation, and not combined with another intervention (e.g., cognitive-behavioral therapy with medication). Fourth, outcome measures were standardized psychometric instruments for determining severity of depressive symptomatology. Where more than one measure was used, each measure was coded independently.

Initial screening of articles was conducted by the second author and a research assistant independently reading the title and abstract of each manuscript and including or excluding the article based on the four eligibility criteria. In the event it was unclear from the abstract or title that the article met each of the eligibility criteria, the article was retained in the search rather than excluding it at this initial stage. In cases of research syntheses, articles included were added to the list of articles screened for inclusion, removing duplicates as necessary. Article assessment and selection was performed independently by the second and third authors, with disagreements between reviewers resolved by consensus.

Data collection and analysis

A data collection sheet was developed by the research team and pilot tested using five randomly selected articles. The second author performed all data extraction, with the third author independently checking the extracted data on 100% of the studies. Disagreements were resolved through discussion. In the event no agreement could be made, the first author acted as the tie-breaker. Information extracted from each article included the following: (a) characteristics of participants (mean age, % female, and race), (b) type of medication administered, (c) treatment length, (d) study design, and (e) measures of effect along with raw scores when available. Because the objective of this analysis was to be as inclusive as possible, the authors hypothesized that effect sizes of individual studies may differ as a result of study design.

Two meta-analyses were performed. First, Response Rate (RR) was calculated for children and adolescents with MDD to treatment with psychopharmacologic medication. Although response rate is not a standard effect measure, it does allow for the inclusion of summary data from studies that may not have had a control condition. Second, an experimental odds ratio (OR) and 95% confidence intervals were calculated for all studies using response rates from the studies versus the average response to placebo (RR = 49.15%) and weighted to the treatment n. For example, if the treatment group (n = 10) had 6 responders, the placebo condition was determined as n = 10 with 5 (10 x 0.4915) responders for OR = (6/10)/(5/10); OR = 1.2. The OR was calculated for two reasons: (a) it provides a standard measure of effect that is recognized in medical research and (b) it provides an index of how each study’s results relate to the standard response rate.

The meta-analyses were then performed using SPSS v. 22 and Comprehensive Meta-analysis (v. 2.2) employing a random-effects model. In order to account for studies that included more than one outcome measure, the most conservative measure (determined by ranking total effects from each measure across studies) was used. In the event a study did not provide data on moderating variables (e.g., age, % female) the mean of the included studies was used. Studies were then weighted by the inverse of the variance consistent with procedures set forth by Lipsey and Wilson [28].

Risk of publication bias

The probability of a treatment effect reported in a systematic review resembling the truth depends on the validity of the studies included in the analysis because certain methodological characteristics may be associated with effect sizes [29,30]. Therefore, it is important to determine whether the obtained sample of studies were representative of the totality of research conducted on the efficacy of psychotropic medications to treat childhood and adolescent depression. The possibility of bias resulting from a tendency of only positive findings being published – known as the “file drawer effect” – was added addressing two methods: calculating the fail-safe N [31] and the p-curve approach [32]. The fail-safe N is determined by calculating the number of studies with an average null result necessary to make the overall results insignificant. The p-curve was introduced to account for “p-hacking”, a theory asserting that researchers may be able to get most studies to find positive results through differing statistical methods [32]. The p-curve assesses the skew of the p-values reported to determine if p-hacking has occurred. Essentially, data that skews to the right is evidence of little or no p-hacking, whereas data skewing to the left may be evidence of p-hacking.
Additional analyses

In primary studies, regression is used to determine the relation between one or more moderators and a dependent variable. The same approach is essentially used with meta-regression except that the covariates are at the level of the study rather than the level of the participant, and the dependent variable is the effect size in the studies rather than participant scores [23]. In the present study, fixed-effects model meta-regressions were computed using response rate to medication with the following moderator variables: age, gender, treatment length, study design, medication class, and measurement instrument. Categorical data (medication class and study design) were dummy coded into binary data where each category was coded individually as "yes" = 1 "no" = 0. The following statistic was used to test the significance of the slope(s):

\[
Z = \frac{B}{SE_B}
\]

Results

Study selection

A total of 38 studies involving 14 different prescribed antidepressant medications were identified for inclusion in the analysis. Figure 1 provides a diagram of the study selection process in accordance with the PRISMA (2009) standards. The search of Medline, Psych INFO, and ERIC databases resulted in a total of 2,311 citations after removal of duplicates, with 23 articles included from previous reviews. Of the 2,334 citations, 2,267 were excluded after reviewing titles and abstracts. The 67 remaining manuscripts were read in their entirety resulting in 38 studies meeting all inclusion criteria and being incorporated into the meta-analysis (Figure 1).

Study characteristics

The majority of studies (n=22) were Randomized Placebo-Controlled Trials (RCTs), followed by open-label studies (n=11), and comparison designs (n=5). Treatment length ranged from four and 12 weeks, with the majority of studies (n = 19) employing an 8-week treatment phase (not including added "placebo lead-ins").

Participants: A total of 2,328 participants from the 38 studies received antidepressant medication treatment. In addition, there were a total of 1,627 placebo participants in the included 22 randomized controlled trials. Sample sizes of the included studies ranged from 3 to 185 (M = 56.75, SD = 55.47). Participant characteristic means were calculated by using the study mean and weighting each study in SPSS by the n of each study’s treatment condition. Mean age of the participants ranged from 9.1 to 18.8 years old with a weighted mean of 13.92 (SD = 13.48), and the ‘other’ category (RR = 52.92%, SD = 8.95). Of the SSRIs, Sertraline (RR = 67%) had the highest response rate, followed by Escitalopram (RR = 64%), and Fluoxetine (RR = 63%), while Citalopram performed the poorest (RR = 52%). Amitriptyline, a TCA, had a Response rate of 76%, although the three studies examining its impact amounted to a modest total participant n of 34. In the ‘other’ category, Venlafaxine had the highest average response rate (RR = 76%), followed by Bupropion (RR = 73%) however, only one study examined Bupropion’s impact with only 11 participants and an open-label design. Finally, a total of 1,180 participants responded to placebo conditions in the RCT studies from a total of 2,401 placebo participants for a placebo response rate of 49.15%.

Odds ratios: Response rates were calculated into Odds Ratios for all studies using the response rate from included studies versus the average response to placebo (RR = 49.15%) and weighted by the inverse variance. The odds of responding to SSRI medication were 1.582 times the odds of responding to the average placebo response (95% CI 1.37-1.82, p = 0.000). The odds of responding to TCAs were 1.163 times the odds of responding to the average response to placebo (RR = 76%), followed by Bupropion (RR = 73%) however, only one study examined Bupropion’s impact with only 11 participants and an open-label design. Finally, a total of 1,180 participants responded to placebo conditions in the RCT studies from a total of 2,401 placebo participants for a placebo response rate of 49.15%.

Syntheses of medication results

Response rates: Syntheses of each medication classification and medication were completed using the response rates from each study. Each study was weighted by the treatment n. Mean RR for SSRI medication was 60.79% (SD = 8.47), followed by TCAs (RR = 54.22%, SD = 13.48), and the ‘other’ category (RR = 52.92%, SD = 8.95). Of the SSRIs, Sertraline (RR = 67%) had the highest response rate, followed by Escitalopram (RR = 64%), and Fluoxetine (RR = 63%), while Citalopram performed the poorest (RR = 52%). Amitriptyline, a TCA, had a Response rate of 76%, although the three studies examining its impact amounted to a modest total participant n of 34. In the ‘other’ category, Venlafaxine had the highest average response rate (RR = 76%), followed by Bupropion (RR = 73%) however, only one study examined Bupropion’s impact with only 11 participants and an open-label design. Finally, a total of 1,180 participants responded to placebo conditions in the RCT studies from a total of 2,401 placebo participants for a placebo response rate of 49.15%.

Medications: Three classes of medications were used, with selective serotonin-reuptake inhibitors (SSRIs) being researched most frequently (n = 21), followed by tricyclic antidepressants (TCAs; n = 13), and a category listed as ‘other’ (n = 4) comprised of medications that do not easily fit into either medication classification. Of the SSRIs, Fluoxetine was the most heavily studied (n = 6), followed by Citalopram (n = 4) and Paroxetine (n = 4), Sertraline (n = 3), and Escitalopram (n = 2) and Nefazodone (n = 1). Tricyclic antidepressants receiving examination included Amitriptyline (n = 3), Clomipramine (n = 1), Desipramine (n = 3), Imipramine (n = 3), and Nortriptyline (n = 3). In the ‘other’ category, Venlafaxine was researched in two studies followed by Azalopram (n = 1), and Bupropion (n = 1).
| Source         | Treatment n | % female | Mean Age | Treatment Length | Measure | Design | Response Rate | Odds Ratiob | Odds Ratioc | Lower Limitd | Upper Limitd |
|----------------|-------------|----------|----------|------------------|---------|--------|---------------|-------------|-------------|---------------|---------------|
| Amitriptyline  | 13          | 70       | 16.1     | 10               | HDRS    | RCT    | 69%           | 0.900b      | 2.625c      | .527          | 13.068        |
| Kashani et al. | 9           | 11       | 10.8     | 8                | BDI     | RCT    | 67%           | 7.000b      | 2.500c      | .370          | 16.888        |
| Kye et al.     | 12          | 29       | 14.6     | 8                | HAM-D   | RCT    | 92%           | 1.222b      | 11.00c      | 1.061         | 114.086       |
|                | Total 34    |          |          |                  |         |        | 76%           | 1.825b      | 3.523c      | 1.179         | 10.568        |
| Alprazolam     | 9           | 70       | 14.12    | 8                | CGI-I   | Comp.  | 67%           | -           | 2.500c      | .370          | 16.888        |
|                | Total 9     |          |          |                  |         |        | 67%           | -           | 2.500c      | .365          | 17.122        |
| Bupropion      | 11          | 45       | 15.5     | 8                | CGI-I   | Open   | 73%           | -           | 3.200c      | .540          | 18.980        |
|                | Total 11    |          |          |                  |         |        | 73%           | -           | 3.200c      | .532          | 19.262        |
| Citalopram     | 55          | 54       | 16       | 8                | CGI-I   | Comp.  | 58%           | -           | 1.443c      | .680          | 3.063         |
|                | Total 55    |          |          |                  |         |        | 58%           | -           | 1.443c      | .657          | 3.169         |
| Desipramine    | 55          | 54       | 16       | 8                | CGI-I   | RCT    | 63%           | 1.541b      | 1.768c      | 1.076         | 2.905         |
|                | Total 65    |          |          |                  |         |        | 64%           | 1.575b      | 1.686c      | 1.246         | 2.629         |
| Escitalopram   | 154         | 59       | 14.5     | 8                | CGI-I   | RCT    | 64%           | 1.606b      | 1.847c      | 1.170         | 2.916         |
|                | Total 283   |          |          |                  |         |        | 64%           | 1.575b      | 1.686c      | 1.246         | 2.629         |
| Fluoxetine     | 13          | 77       | 18.8     | 12               | CGI-I   | Open   | 100%          | -           | 31.514c     | 1.533         | 633.140       |
|                | Total       |          |          |                  |         |        | 100%          | -           | 31.514c     | 1.533         | 633.140       |
| Imipramine     | 6           | 70       | 14.1     | 8                | CGI-I   | Comp.  | 67%           | -           | 2.000c      | .202          | 4.955         |
| Hughes et al.  | 13          | 55.3*    | 14.1*    | 6                | CDRS-R  | RCT    | 56%           | 2.000b      | 1.000c      | .202          | 4.955         |
| Keller et al.  | 94          | 59       | 14.9     | 8                | HAM-D   | RCT    | 50%           | 1.175b      | 1.043c      | .589          | 1.849         |
| Petli & Law    | 5           | 55.3*    | 9.2      | 4                | SADLI   | RCT    | 100%          | 11.667b     | 11.667c     | .322          | 422.139       |
| Puig-Antich et al. | 16         | 60.5     | 9.1      | 5                | KSADS   | RCT    | 56%           | 0.600b      | 1.286c      | 0.320         | 5.169         |
|                | Total 132   |          |          |                  |         |        | 52%           | 1.080b      | 1.145c      | 0.693         | 1.931         |
| Nefazodone     | 28          | 42       | 14.2     | 8                | CGI-I   | Open   | 79%           | -           | 3.667c      | 1.41          | 11.787        |
|                | Total 38    |          |          |                  |         |        | 76%           | -           | 3.219c      | 1.181         | 8.737         |
| Nortriptyline  | 22          | 27       | 9.23     | 8                | CDRS-R  | Open   | 64%           | -           | 1.750c      | 0.524         | 5.842         |
|                | Total 60    |          |          |                  |         |        | 38%           | 1.691b      | 0.660c      | 0.298         | 1.451         |
| Paroxetine     | 177         | 67       | 15.5     | 12               | MADRS   | RCT    | 60%           | 1.096b      | 1.581c      | 1.037         | 2.410         |
| Braconnier et al. | 59          | 67       | 16       | 8                | CGI-I   | Comp.  | 59%           | -           | 1.509b      | 0.728         | 3.125         |
| Emslie et al.  | 101         | 47       | 12       | 8                | CGI-I   | RCT    | 49%           | 1.106b      | 0.961c      | 0.554         | 1.669         |
| Keller et al.  | 90          | 62       | 14.8     | 8                | HAM-D   | RCT    | 63%           | -           | 1.806c      | 0.996         | 3.276         |
| Noble et al.   | 7           | 29       | 14.4     | 12               | CGI-I   | Open   | 71%           | -           | 3.333c      | 0.362         | 30.701        |
In terms of individual SSRI medications, Sertraline was the most effective SSRI (OR = 2.073, 95% CI 1.42-3.02, \( p = 0.000 \)) followed by Escitalopram (OR = 1.811, 95% CI 1.29-2.53, \( p = 0.001 \)), and Fluoxetine (OR = 1.700, 95% CI 1.27-2.27, \( p = 0.000 \)), while Citalopram once again yielded the poorest results (OR = 1.117, 95% CI 0.783 - 1.593, \( p = 0.541 \)). The only TCA to show significant findings over the average placebo response was Amitriptyline (OR = 3.523, 95% CI 1.19-10.46, \( p = 0.023 \)). In the ‘other’ category, Nefazodone yielded the highest response compared to average placebo (OR = 3.219, 95% CI 1.202-8.620, \( p = 0.020 \)), although the number of participants was small (\( n = 38 \)). None of the other medications in the ‘other’ category were significant over the average placebo despite relatively high Odds Ratios in two: Bupropion (OR = 3.200, 95% CI 0.54-18.98, \( p = 0.200 \)) and Alprazolam (OR = 2.50, 95% CI 0.37-16.89, \( p = 0.347 \)).

### Risk of Publication Bias Within Studies

The possibility of bias in publication resulting from a tendency of only positive findings being published was assessed through two methods: (a) Rosenthal’s fail-safe \( N \) (Rosenthal, 1979) and the \( p \)-curve approach [32]. Table 2 provides results of analyses related to publication bias (Table 2).

#### Fail-Safe \( N \)

The fail-safe \( N \) was calculated for each class of medication and each individual medication (provided more than two studies were present) using the experimental Odds Ratio calculated from the aggregate placebo response rate of the included studies with placebo controls. Of the classifications of medications, only SSRIs had statistically significant positive findings and those positive findings would require 184 studies with null findings to bring the \( p \) value to insignificant levels. The most significant findings from SSRI medications with more than five studies were for Fluoxetine, which would require 19 null studies to bring the \( p \) value to >0.05 followed by Paroxetine and Sertraline. Further, Amitriptyline was the only TCA with positive findings and would require only two studies with null findings to invalidate the results.

#### \( p \)-Curve

The \( p \)-curve was applied to account for \( p \)-hacking [32], a theory suggesting that studies may have utilized certain statistical procedures to ensure finding positive results. In calculating the \( p \)-curve, only medications or classifications of medications with more than five studies were included. Results indicated that neither the extant SSRI literature (\( p = .1104 \)) nor the specific medication Fluoxetine (\( p = .5328 \)) have sufficient evidence in their findings, although there does not appear to be evidence that the literature has been \( p \)-hacked. Furthermore, the TCA literature lacks evidence of findings (\( p = 0.1979 \)) and nearly has evidence to suggest that it has been \( p \)-hacked (\( p = 0.0648 \)).

### Additional Analyses

#### Meta-Regressions

Meta-regressions were performed to determine which of the moderator variables predicted response rate to medication. Of the medication classes coded, not being a TCA (\( t = -10.052, \( p = 0.000 \)) or the ‘other’ category (\( t = -2.975, \ p = 0.003 \)) significantly predicted response rate. Of the designs employed, only open-label trials significantly predicted RR (\( t = 2.927, \ p = 0.004 \)). Further, % of females in the study (\( t = -2.742, \ p = 0.006 \)) and participant age (\( t = 3.389, \ p = 0.001 \)) significantly predicted response rate to treatment.

#### ANOVAs

Two analyses of variance (ANOVA) were performed to determine if certain medication classes or study designs significantly affected the response rates to medication. Regarding medication classes, differences between groups were significant (\( F [2,887] = 5.075, \ p = 0.007 \)). Scheffe post-hoc tests were then performed to examine individual differences with SSRIs significantly outperforming the TCA category (\( M = 0.0515, \ p = 0.010 \)), but not the ‘other’ category (\( M = 0.0215, \ p = 0.353 \)). Further, the ‘other’ category was also associated with higher response rates than TCAs (\( M = 0.03004, \ p = 0.342 \)) but not SSRIs (\( M = 0.0215, \ p = 0.353 \)). Of the study designs, differences between groups were significant (\( F [2,887] = 9.598, \ p = 0.000 \)) with both randomized control-trials (\( M = 0.03266, \ p = 0.001 \)) and open-label trials (\( M = 0.05558, \ p = 0.001 \)) significantly impacting response rates compared to comparison trials. However, there was no significant difference between RCTs and open-label trials in terms of response rate.

### Discussion

Results of the present analysis can be summarized as follows: The majority of studies had Caucasian participants and the percentage of participants who were African-American and Hispanic from the few studies that included them were very low. When there were sufficient studies, the most effective class of medication was SSRIs with Sertraline having the highest response rate and Citalopram the lowest response rate. However, regardless of medication class, overall Nefazodone was the medication with the highest response rate. It is important that this finding is interpreted cautiously because it is based on only 38 participants. Although Amitriptyline and Bupropion had response rates higher than the SSRIs, the number of studies for each (\( N = 3, \ N = 1 \)), respectively, was small. In terms of risk of bias, it is unlikely that the extant SSRI literature suffers from the file drawer problem because it would take 184 studies with null findings to bring the \( p \) value to

| Total | 434 | Sertraline | 58% | 1.308a | 1.530a | 1.080 | 1.947 |
|-------|-----|------------|-----|--------|--------|-------|-------|
| Melvin et al. [81] | 26  | 73 | 15 | 12 | GAF | Comp. | 46% | - | 0.857a | 0.289 | 2.546 |
| Nixon et al. [38] | 23  | 67 | 15 | 12 | HAM-D | Open | 74% | - | 3.0911 | 0.895 | 10.672 |
| Wagner et al. [81] | 185 | 51 | 12 | 10 | CDRS-R | RCT | 69% | 1.5432 | 2.2622 | 1.481 | 3.455 |
| Total | 234 | - | - | - | - | - | - | - | - | - | - |

| Venlafaxine | 67% | 1.5432 | 2.0732 | 1.345 | 3.100 |
| Brent et al. [82] | 166 | 68 | 15.6 | 12 | CGI-I | Comp. | 48% | - | 0.9532 | 0.620 | 1.466 |
| Emslie et al. [83] | 169 | 46 | 12.2 | 8 | HAM-D | RCT | 51% | 1.1032 | 1.0872 | 0.708 | 1.069 |
| Total | 335 | - | - | - | - | - | - | - | - | - | - |

*mean of all included studies used due to missing data

1 Odds Ratio calculated from Study Placebo Condition

2 Odds Ratio Calculated from Estimated Placebo response rate of 49.15%

BDI=Beck Depression Inventory, CDRS-R = Children's Depression Rating Scale – Revised, CGI-I = Clinical Global Impression – Improvement, HAM-D = Hamilton Rating Scale for Depression, KSADS = Kiddie-SADS-Psychiatric Evaluation Schedule, MDD=Major Depressive Disorder, PIC = Primary Depressive Illness, P-Curve: P-hacking [32] -hacked (*)

Table 1: Summary of Included Studies Evaluating Antidepressant Medication in Children and Adolescents.
Publication Bias: The “File Drawer Problem”

The “file drawer problem” was articulated by Rosenthal [31] approximately 35 years ago. Basically, research on a given topic that has not been published (i.e., nonsignificant results) cannot be determined. This systematic omission from the literature may distort an effect size obtained from a meta-analysis and that the exaggerations are strongest when the true effect size approaches zero [25]. In the present study, results of the Fail-Safe N reflect how fragile “significant effects” from a body of literature can be. For example, Amitriptyline, the only TCA with positive findings, would only require two studies with null results to invalidate its effectiveness. On a positive note, for the statistically significant findings of SSRIs to be invalidated would require 184 studies with null findings. The most significant SSRI finding was for Fluoxetine, which would require 19 null studies. Ironicaly, in the present study, Fluoxetine was one of the least effective SSRIs, yet it is the only medication in which there was the most confidence that it is the only medication in which there was the most confidence that it was more effective than placebo, there was some evidence suggesting they had been p-hacked.

Although attempts, such as the two procedures used in the present analysis to account for the file drawer problem, have often been undertaken by researchers, some unknowable number of nonsignificant findings remain unrecoverable. Furthermore, Kromrey and Rendina-Gobioff [41] concluded that current statistical methods to account for publication bias may fail to control Type I error rates or lack sufficient power. Therefore, Howard et al. [42] proposed a different way of addressing the file drawer problem using the example of the psychotherapy efficacy literature. Rather than correcting for bias statistically, they suggested performing a new mini-literature review meta-analysis of all their new studies and whether the results reached the same conclusions regarding which class and type of medication is the most efficacious for children and adolescents. However, the current analysis was the first to statistically compare medications and, within the class of SSRIs, determine that Sertraline had the highest response rate while Citalopram the lowest response rate. Relatdly, Pfalzgraf et al. [40] surveyed child psychiatrists and found that the antidepressants of choice tended to be the SSRI fluoxetine or sertraline - a finding that is consistent with the results of the present meta-analysis.

Table 2: Summary of Fail-Safe-N for included studies by medication and classification.

| Medication | Z     | P     | # of studies necessary to bring p-value to >alpha | Right Skewed (Evidence) | Flatter than 33% (Lack Evidence) | Left-skewed (lack evidence and p-hacked) |
|------------|-------|-------|-----------------------------------------------|-------------------------|-----------------------------------|----------------------------------------|
| SSRIs      | 6.24790 | 0.0000 | 184                                           | X^2(12)=18.18, p=0.1104 | X^2(12)=11.6, p=0.4787            | X^2(12)=6.36, p=0.8966                |
| Citalopram | 1.06905 | 0.3129 | 0                                             | -                       | -                                 | -                                      |
| Escitalopram* | -    | -     | -                                             | -                       | -                                 | -                                      |
| Fluoxetine | 3.94061 | 0.0008 | 19                                            | X^2(4)=3.15, p=0.5328   | X^2(4)=4.6, p=0.3308              | X^2(4)=2.46, p=0.6519                 |
| Paroxetine | 2.73201 | 0.00633 | 5                                             | -                       | -                                 | -                                      |
| Sertraline | 3.04984 | 0.00229 | 5                                             | -                       | -                                 | -                                      |
| TCAs       | 1.30166 | 0.19303 | 0                                             | X^2(4)=0.46, p=0.977    | X^2(4)=11.7, p=0.0197*            | X^2(4)=8.86, p=0.0648                 |
| Amitriptyline | 2.38321 | 0.01716 | 2                                             | -                       | -                                 | -                                      |
| Clomipramine* | -    | -     | -                                             | -                       | -                                 | -                                      |
| Desipramine | 0.02107 | 0.98319 | 0                                             | -                       | -                                 | -                                      |
| Imipramine | 1.08406 | 0.27834 | 0                                             | -                       | -                                 | -                                      |
| Nortriptyline | -1.44434 | 0.14864 | 0                                             | -                       | -                                 | -                                      |
| Other      | 2.23309 | 0.02554 | 2                                             | X^2(2)=1.08, p=0.5837   | X^2(2)=2.95, p=0.2288             | X^2(2)=1.75, p=0.4163                 |
| Azapramol* | -     | -     | -                                             | -                       | -                                 | -                                      |
| Buproprin* | -     | -     | -                                             | -                       | -                                 | -                                      |
| Venlafaxine* | -    | -     | -                                             | -                       | -                                 | -                                      |
| Nefazadone* | -    | -     | -                                             | -                       | -                                 | -                                      |

*Too few studies to calculate Fail-Safe N

nonsignificant levels. Similarly, the SSRI literature does not appear to be plagued p-hacking, however TCAs tended toward being p-hacked. In terms of moderator variables, not being a TCA or ‘other’ medication predicted response rate, while open-label trials was the only design that predicted response rate, and age and gender (females) predicted response rate to treatment. Specifically, as the age of participants increases, so too does their response rate to medication. Also, the lower the percentage of female participants, the higher the response rates. Of the study designs, RCT’s and open-label trials resulted in significantly higher response rates than did comparison trials.

Medication class, type, and efficacy

It was not easy to reach unequivocal conclusions regarding which class and type of medication was the most efficacious. The reason was because some medications (e.g., Amitriptyline, Bupropin) had too few studies and participants to determine their differential efficacy with any veracity. Response rates and odds ratios were calculated and both indicated that SSRIs were more effective than TCIs and medications in the ‘other’ category when sufficient studies and participants existed. These results are consistent with past research in which TCAs have repeatedly been found to be no more effective than placebo and present the possibility of severe, even lethal side effects [7,8,20,37].

Another important point in determining differential efficacy of medication involves the three phases with which depression is treated: acute, continuation, and maintenance. Boylan et al. [1] stated that most studies in children and adolescents have evaluated treatments during the acute phase, with only one controlled trial for continuation [38] and no maintenance studies. Therefore, recommendations regarding medication efficacy during the continuation and maintenance treatments must be extrapolated from the adult literature, but there are a variety of pharmacokinetic differences that may impact how youngsters respond to medication during these phases [39].

At this juncture, there are simply too few studies to reach definitive conclusions regarding which class and type of medication is the most efficacious for children and adolescents. However, the current analysis was the first to statistically compare medications and, within the class of SSRIs, determine that Sertraline had the highest response rate while Citalopram the lowest response rate. Relatdly, Pfalzgraf et al. [40] surveyed child psychiatrists and found that the antidepressants of choice tended to be the SSRI fluoxetine or sertraline - a finding that is consistent with the results of the present meta-analysis.

Summary of Fail-Safe-N for included studies by medication and classification.
presumably biased (i.e., file drawer effect) - literature, or whether results were closer to the null value ($d = 0.00$). Clearly, the solutions to the file drawer problem present a vexing and challenging issue to meta-analytic research and it will likely take a paradigm shift to truly address this problem such as authors submitting only their literature review and methods, abandoning conventional inferential statistics in favor of Bayesian approaches, or registering studies and protocols online prior to conducting a study [43].

Age, gender, and response rates

In the present analysis, participants’ response rates to medication increased as did their age. This finding is congruent with results of previous reviews [6] and also data indicating that some neurotransmitter systems related to affect are not fully mature during childhood and adolescence [39]. Moreno et al. [39] described a myriad of pharmacokinetics that impact children and adolescents’ response to antidepressants compared to adults such as lower absorption rate, increased metabolism rate, reduced level of drug protein binding, and more permeable blood-brain barrier. They also believed that the typical approach for children and adolescents - based on adult studies - of proportionally reducing doses by body weight may result in non-therapeutic levels that would yield negative results. Results from the present analysis partially confirm this assumption because older participants had a greater response rate than younger participants, but refuted it because significant effects were obtained for all aged participants. Therefore, in the lack of a pediatric dosing protocol, the present approach seems sufficient and appropriate.

Gender differences in the prevalence, phenomenology, and natural history of MDD have been well documented. The rate of MDD is approximately equal between boys and girls, but during adolescence, there is a dramatic increase in depression among females, and that trend continues through adult life [44,45]. Although men and women differ in the metabolism and distribution of antidepressants, actual gender differences in terms of response rate remains a controversial topic that is marked by individual-specific variability that may be due, in part, to genetic disparities [44]. In the present study, the lower the percentage of female participants, the higher the response rates. However, gender and age interact and influence each other. Participants response rate improved the older they got and with fewer females.

Design

In terms of study design, randomized control trials and open-label trials had participants with significantly better response rates than participants in comparison trials. However, there were no differences in response rate between randomized control-trials and open-label trials. A similar result was obtained by Biederman et al. [46] who conducted a meta-analysis of open-label versus randomized, placebo-controlled trials to predict results of psychopharmacologic treatments for pediatric bipolar disorder. They concluded that open-label trials are useful predictors of the potential safety and efficacy of a psychopharmacologic agent to treat youth with bipolar disorder. It may come down to a clinical judgment of perceived risk whether to expose patients to randomized placebo control-trials versus open-label trials. For example, in a sample of adults receiving antidepressive treatment, Deuschle et al. [47] found no difference between each research design in terms of clinical outcome, but suggested that randomized control-trials may expose patients to an increased risk of adverse events compared to the open condition. This increased risk is mitigated in most other fields of medicine by using a standard of care (SOC) guideline as the control condition. For example, the American Society of Clinical Oncology (ASCO; 2014) publishes guidelines for the most current SOC for treating each type of cancer [48]. Those standards of care are then used to inform quality of practices used by physicians and to guide subsequent clinical trials that use the SOC as a control condition with other treatments compared to it, thereby ensuring that the patient is not exposed to increased risk. Unfortunately, the field of psychiatry has relatively vague guidelines for treating depression in adults [48] allowing for the use of a variety of pharmacotherapies (e.g., SSRIs, SNRIs, Bupropion), psychotherapy, or other somatic therapies (e.g., electro-convulsive therapy), making the systematic study of any treatment modality against a SOC difficult.

Conclusion

Major depressive disorder in children and adolescents has been the topic of much research including, but not limited to, diagnosis, assessment, prevalence, characteristics, and treatment. In the latter case, most of the research points to cognitive-behavioral therapy and psychopharmacology - or a combination of both - being the most efficacious approaches for treating children and adolescents with MDD. The current review analyzed 38 studies, which is the most to date, in order to address several methodological issues inherent to previous meta-analyses. Specifically, the present review was the first to adhere to the PRISMA standards for reporting systematic reviews and meta-analyses of studies regarding efficacy of psychopharmacologic therapy to treat MDD in children and adolescents. In addition, the current review was the first to statistically compare the efficacy of different classes and types of medication, address publication bias the file-drawer problem presents, and examined various moderator variables.

There are several limitations to the present study. First, there are different data-bases from which studies can be obtained (e.g., Medline versus Pubmed). Also, it is always problematic determining which search terms to input. These considerations may lead to different studies being obtained. That is why the PRISMA statement recommends authors include their search parameters so that replication is possible. Second, there were simply too few studies reviewed to examine the impact of race on the effect of antidepressants to treat MDD in children and adolescents. Third, the outcome measures used were not consistent across studies ranging from a variety of clinician rating scales (e.g., CGI-I) to depression inventories (e.g., BDI), thus results should be treated with caution. Fourth, the results regarding the differential efficacy of antidepressants must be evaluated carefully because of the small number of studies and/or participants in individual studies for certain classes and types of medication. For example, in the present review, there were only one study a piece on the response rates of Azalopram and Bupropion. By far, the most research has been conducted on SSRIs, but the comparative efficacy of medications within this class has been sparse. There is also little research on the comparative efficacy of SSRIs versus third generation antidepressants that make up the serotonin-norepinephrine-dopamine reuptake inhibitors (SNDRIs). Among adults, Oliver et al. [49] found third generation antidepressants to be just as effective and safe as the previous class of SSRIs. A final area for future study needs to address socioeconomic status and ethnicity upon response rate to antidepressants. Especially important is ensuring that future meta-analyses adhere to the PRISMA standards and, regardless of the study design, participants receive a treatment as is typical in other areas of medical treatment.

References

1. Boylan K, Romero S, Birmaher B (2007) Psychopharmacologic treatment of pediatric major depressive disorder. Psychopharmacology (Berl) 191: 27-38.
2. Jane Costello E, Erkanli A, Angold A (2006) Is there an epidemic of child or adolescent depression? J Child Psychol Psychiatry 47: 1263-1271.

3. Birmaher B, Arbelaez C, Brent D (2002) Course and outcome of child and adolescent major depressive disorder. Child Adolesc Psychiatr Clin N Am 11: 619-637.

4. Ambrosini PJ (2000) A review of pharmacotherapy of major depression in children and adolescents. Psychiatr Serv 51: 627-633.

5. Food and Drug Administration Center for Drug Evaluation and Research. Revisions to product labeling.

6. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, et al. (2007) Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. JAMA 297: 1633-1639.

7. Birmaher B, Ryan ND, Williamson BA, Brent D, Kaufman J (1996) Childhood and adolescent depression: A review of the past 10 years. Part II. J Am Acad Child Adolesc Psychiatry 35: 1575-1583.

8. Geller B, Reising D, Leonard HL, Riddle MA, Walsh BT (1999) Critical review of tricyclic antidepressant use in children and adolescents. J Am Acad Child Adolesc Psychiatry 38: 513-518.

9. Henley A, Kisicki MD, Varley C (2012) Efficacy and safety of antidepressant drug treatment in children and adolescents. Mol Psychiatry 17: 1186-1193.

10. Sommers-Flanagan J, Sommers-Flanagan R (1996) Efficacy of antidepressant medication with depressed youth: What psychologists should know. Professional Psychology: Research and Practice 27: 145-153.

11. Maalouf FT, Atwi M, Brent DA (2011) Treatment-resistant depression in adolescents: review and updates on clinical management. Depress Anxiety 28: 946-954.

12. Vasa RA, Carlino AR, Pine DS (2006) Pharmacotherapy of depressed children and adolescents: current issues and potential directions. Biol Psychiatry 59: 1021-1028.

13. Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA (2009) Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 166: 42-49.

14. Cohen D, Consoli A, Bodeau N, Purper-Wufact D, Deniau E, et al. (2010) Predictors of placebo response in randomized controlled trials of psychotropic drugs for children and adolescents with internalizing disorders. J Child Adolesc Psychopharmacol 20: 39-47.

15. Dubicka B, Hadley S, Roberts C (2006) Suicidal behaviour in youths with depression treated with new-generation antidepressants: meta-analysis. Br J Psychiatry 189: 393-398.

16. Hetrick SE, Cox GR, Merry SN (2011) Treatment-resistant depression in adolescents: is the addition of cognitive behavioral therapy of benefit? Psychol Res Behav Manag 4: 97-112.

17. Hetrick SE, McKenzie JE, Merry SN (2010) The use of SSRIs in children and adolescents. Curr Opin Psychiatry 23: 53-57.

18. Thurber S, Ensign J, Punnnett AF, Welter K (1995) A meta-analysis of antidepressant outcome studies that involved children and adolescents. J Clin Psychol 51: 340-345.

19. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Colgrove A, et al. (2004) Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363: 1341-1345.

20. Rutherford BR, Sneed JR, Tander MJ, Rindskopf D, Peterson BS, et al. (2011) Deconstructing pediatric depression trials: An analysis of the effects of expectancy and therapeutic contact. J Am Acad Child Adolesc Psychiatry 50: 782-795.

21. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses: explanation and elaboration. PLoS Medicine 6: e1000100.

22. Sussman N (2004) The “file drawer” effect: Assessing efficacy and safety of antidepressants. Primary Psychiatry 11: 12.

23. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR (2009) Introduction to meta-analysis. John Wiley & Sons, England.

24. Cooper HM (2010) Research synthesis and meta-analysis. (4th Edn.), SAGE Publications, Los Angeles.

25. Bradley MT, Gupta RD (1997) Estimating the effect of the file drawer problem in meta-analysis. Perceptual & Motor Skills 85: 719-722.

26. Rothstein HR, Sutton AJ, Borenstein M (2005) Publication bias in meta-analysis. John Wiley & Sons, West Sussex, England.

27. Deuschle M, Rumm B, Bindeballe N, Colla M, Hamann B, et al. (2004) Open-label non-randomized versus double-blind randomized antidepressive treatment: What are the advantages of clinical decision over randomization. Pharmacopsychiatry 37: 229-302.
48. American Society of Clinical Oncology (2014) American Society of Clinical Oncology quality and guidelines.

49. Oliver JS, Burrows GD, Norman TR (2001) Third-generation antidepressants: do they offer advantages over the SSRIs? CNS Drugs 15: 941-954.

50. Birmaher B, Waterman G, Ryan N, Perel J, McNabb J, et al. (1998). Randomized, controlled trial of amitriptyline versus placebo for adolescents with “treatment-resistant” major depression. J Am Acad Child Adolesc Psychiatry 37: 527-535.

51. Kye CH, Waterman GS, Ryan ND, Birmaher B, Williamson DE, et al. (1998) A randomized, controlled trial of amitriptyline in the acute treatment of adolescent major depression. J Am Acad Child Adolesc Psychiatry 35: 1139-1144.

52. Bernstein GA, Garfinkel BD, Borchardt CM (1990) Comparative studies of pharmacotherapy for school refusal. J Am Acad Child Adolesc Psychiatry 29: 773-781.

53. Glod CA, Lynch A, Flynn E, Berkowitz C, Baldessarini RJ (2003) Open trial of bupropion SR in adolescent major depression. J Child Adolesc Psychiatr Nurs 16: 123-130.

54. Shirazi E, Alfaghand-Rad J (2005) An open trial of citalopram in children and adolescents with depression. J Child Adolesc Psychopharmacol 15: 233-239.

55. Chirman S, Kronenberg S, Aptil A, Brent D, Melhem N, et al. (2010) Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study. J Neural Transm 117: 139-145.

56. von Knorrall AO, Olsson GI, Thomsen PH, Lemming OM, Hultén A (2006) A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder. J Clin Psychopharmacol 26: 311-315.

57. Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, et al. (2004) A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. J Psychiatry 181: 1079-1083.

58. Bracconier A, Le Coent R, Cohen D (2003) Paroxetine versus clomipramine in adolescents with severe major depression: A double-blind, randomized, multicenter trial. J Am Acad Child Adolesc Psychiatry 42: 22-29.

59. Boulos C, Kutcher S, Marton P, Simeon J, Ferguson B, et al. (1991) Response to desipramine treatment in adolescent major depression. Psychopharmacol Bull 27: 59-65.

60. Klein R, Mannuzza S, Koplewicz H, Tancer N, Shah M, et al. (1998) Adolescent depression: Controlled desipramine treatment and atypical features. Depress Anxiety 7: 15-31.

61. Kutcher S, Boulos C, Ward B, Marton P, Simeon J, et al. (1994) Response to desipramine treatment in adolescent depression: A fixed-dose, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 33: 686-694.

62. Emslie GJ, Ventura D, Korolzer A, Tourkodimitris S (2009) Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. J Am Acad Child Adolesc Psychiatry 48: 721-729.

63. Wagner KD, Jonas J, Findling RL, Ventura D, Saikali K (2006) A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry 45: 280-288.

64. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, et al. (1997) A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54: 1031-1037.

65. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, et al. (2002) Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41: 1205-1215.

66. Goodyer I, Dubicka B, Wilkinson P, Kelvin R, Roberts C, et al. (2007) Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behavioural therapy in adolescents with major depression: randomised controlled trial. BMJ 335: 142.

67. March J, Silva S, Petrycki S, Curry J, Wells K, et al. (2004) Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. JAMA 292: 807-820.

68. Waslick BD, Walsh BT, Greenhill LL, Ellenberg M, Capasso L, et al. (1999) Open trial of fluoxetine in children and adolescents with dysthymic disorder or double depression. J Affecr Disord 56: 227-236.

69. Hughes CW, Preskorn SH, Wrona M, Hassannein R, Tucker S (1990) Followup of adolescents initially treated for prepubertal-onset major depressive disorder with imipramine. Psychopharmacol Bull 26: 244-249.

70. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher SP, et al. (2001) Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 40: 762-772.

71. Petti TA, Law W 3rd (1982) Imipramine treatment of depressed children: a double-blind pilot study. J Clin Psychopharmacol 2: 107-110.

72. Findling RL, Preskorn SH, Marcus RN, Magnus RD, D’Amico F, et al. (2000) Nefazodone pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 39: 1008-1016.

73. Goodnick PJ, Jorge CA, Hunter T, Kumar AM (2000) Nefazodone treatment of adolescent depression: an open-label study of response and biochemistry. Ann Clin Psychiatry 12: 97-100.

74. Geller B, Cooper T, Chestnut E, Anker J, Schluchter M (1986) Preliminary data on the relationship between norotryptiline plasma level and response in depressed children. Am J Psychiatry 143: 1283-1286.

75. Geller B, Cooper TB, Graham DL, Marsteller FA, Bryant DM (1999) Double-blind placebo-controlled study of nortryptiline in depressed adolescents using a “fixed plasma level” design. Psychopharmacol Bull 26: 85-90.

76. Geller B, Cooper TB, Graham DL, Fettner HH, Marsteller FA, et al. (1992) Pharmacologically designed double-blind placebo-controlled study of nortryptiline in 6- to 12-year-olds with major depressive disorder. J Am Acad Child Adolesc Psychiatry 31: 34-44.

77. Berard R, Fong R, Carpenter DJ, Thomason C, Wilkinson C (2006) An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder. Journal of Child and Adolescent Psychopharmacology 16: 59-75.

78. Emslie GJ, Wagner KD, Kutcher S, Krulewicz S, Fong R, et al. (2006) Paroxetine treatment in children and adolescents with major depressive disorder: A randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 45: 709-719.

79. Nobile M, Bellotti B, Marino C, Molteni M, Battaglia M (2000) An open trial of paroxetine in the treatment of children and adolescents diagnosed with dysthymia. J Child Adolesc Psychopharmacol 10: 103-109.

80. Melvin GA, Tonge BJ, King NJ, Heyne D, Gordon MS, et al. (2006) A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. J Am Acad Child Adolesc Psychiatry 45: 1151-1161.

81. Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, et al. (2003) Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: Two randomized controlled trials. JAMA 290: 1033-1041.

82. Brent D, Emslie G, Clarke G, Wagner K, Asarnow J, et al. (2008) Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial. JAMA 299: 901-913.

83. Emslie GJ, Yeung PP, Kunz NR (2007) Long-term, open-label venlafaxine extended-release treatment in children and adolescents with major depressive disorder. CNS Spectr 12: 223-233.